SCHEMBL5134972

SCHEMBL5134972

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCCCC(=O)OC)Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.52
HDAC1 Q13547 3/20 0.42
HDAC3 O15379 2/20 0.42
HDAC2 Q92769 2/20 0.42
HDAC8 Q9BY41 2/20 0.42
NCOR2 Q9Y618 2/20 0.42
C5AR1 P21730 1/20 0.41
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
TLR7 Q9NYK1 1/20 0.38
TP53 P04637 1/20 0.38
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
CYP3A4 P08684 2/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TSHR P16473 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135685 0.94 FAAH (0.52) FAAHHDAC1C5AR1TP53KDM4E
SCHEMBL5072206 0.91 FAAH (0.42) FAAHHDAC1HDAC3HDAC2HDAC8
SCHEMBL5137349 0.86 C5AR1 (0.43) C5AR1KDM4EALDH1A1CYP3A4HPGD
SCHEMBL649161 0.86 C5AR1 (0.47) C5AR1BCHEKDM4EALDH1A1CYP3A4
SCHEMBL5135950 0.85 LPAR1 (0.42) HDAC1C5AR1TLR7PPARGPPARA
Hydrochloric Acid SCHEMBL648480 0.85 C5AR1 (0.46) C5AR1BCHEKDM4EALDH1A1CYP3A4
SCHEMBL5135893 0.84 TLR7 (0.49) C5AR1TLR7
SCHEMBL5138025 0.84 C5AR1 (0.47) C5AR1KDM4EALDH1A1CYP3A4HPGD
SCHEMBL5137376 0.83 C5AR1 (0.42) C5AR1TLR7KDM4EALDH1A1TSHR
SCHEMBL5137962 0.83 C5AR1 (0.44) C5AR1BCHETP53KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed